Piper Sandler Issues Positive Forecast for Kymera Therapeutics (NASDAQ:KYMR) Stock Price

Kymera Therapeutics (NASDAQ:KYMR) had its price target hoisted by Piper Sandler from $125.00 to $140.00 in a research report sent to investors on Thursday,Benzinga reports. The firm currently has an overweight rating on the stock.

Other analysts have also recently issued research reports about the stock. Wells Fargo & Company lifted their price target on shares of Kymera Therapeutics from $69.00 to $116.00 and gave the company an “overweight” rating in a report on Tuesday, December 9th. Bank of America lifted their target price on shares of Kymera Therapeutics from $71.00 to $112.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Mizuho increased their price target on shares of Kymera Therapeutics from $81.00 to $120.00 and gave the stock an “outperform” rating in a research note on Thursday, December 11th. Stifel Nicolaus set a $114.00 price objective on shares of Kymera Therapeutics in a report on Monday, December 8th. Finally, Citigroup upped their target price on Kymera Therapeutics from $80.00 to $110.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $117.60.

Kymera Therapeutics Price Performance

Shares of NASDAQ:KYMR opened at $95.03 on Thursday. The stock’s 50-day moving average is $78.37 and its 200 day moving average is $64.89. The company has a market cap of $6.84 billion, a PE ratio of -26.47 and a beta of 2.21. Kymera Therapeutics has a 1 year low of $19.44 and a 1 year high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). Kymera Therapeutics had a negative return on equity of 32.92% and a negative net margin of 674.81%.The business had revenue of $2.87 million during the quarter, compared to the consensus estimate of $14.80 million. During the same quarter in the prior year, the business posted ($0.88) earnings per share. Kymera Therapeutics’s quarterly revenue was down 60.8% compared to the same quarter last year. Analysts expect that Kymera Therapeutics will post -2.79 EPS for the current fiscal year.

Insider Activity

In related news, CEO Nello Mainolfi sold 100,000 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $89.17, for a total transaction of $8,917,000.00. Following the completion of the transaction, the chief executive officer owned 660,482 shares of the company’s stock, valued at $58,895,179.94. This trade represents a 13.15% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jeffrey W. Albers sold 5,000 shares of Kymera Therapeutics stock in a transaction on Monday, December 8th. The shares were sold at an average price of $89.76, for a total value of $448,800.00. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 450,895 shares of company stock valued at $40,486,151. 16.01% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Kymera Therapeutics

A number of hedge funds have recently bought and sold shares of KYMR. PNC Financial Services Group Inc. grew its position in Kymera Therapeutics by 506.6% during the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock valued at $40,000 after purchasing an additional 770 shares during the last quarter. Smartleaf Asset Management LLC lifted its stake in shares of Kymera Therapeutics by 382.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after buying an additional 424 shares in the last quarter. Larson Financial Group LLC grew its holdings in shares of Kymera Therapeutics by 81.5% during the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after buying an additional 349 shares during the last quarter. Osaic Holdings Inc. grew its holdings in shares of Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after buying an additional 1,083 shares during the last quarter. Finally, Bessemer Group Inc. increased its position in shares of Kymera Therapeutics by 652.0% during the third quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock valued at $53,000 after acquiring an additional 815 shares in the last quarter.

Key Headlines Impacting Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Piper Sandler raised its price target to $140 and reaffirmed an “overweight” rating, signaling strong analyst confidence and implying meaningful upside from current levels. Piper Sandler Raise
• Neutral Sentiment: BTIG trimmed its target slightly from $138 to $134 but kept a “buy” rating — a modest adjustment that maintains institutional support but is not a bearish signal. BTIG Note
• Negative Sentiment: Kymera reported Q4 EPS of ($0.97), missing consensus (loss of $0.77) and posted revenue of $2.87M versus estimates near $14.8M; revenue fell ~60.8% year‑over‑year — a material earnings and top-line miss that increases short-term execution risk. Q4 Results
• Negative Sentiment: CEO Nello Mainolfi sold 30,000 shares for ~$2.71M (filed with the SEC). Insider sales can be interpreted negatively by some investors even though the CEO retains a large stake. Insider Sale
• Neutral Sentiment: Technical/contextual note: the stock is trading well above its 50‑ and 200‑day moving averages and near its 52‑week high, reflecting strong momentum that may amplify both positive analyst headlines and headline-driven volatility.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.